Table 1 Baseline patient characteristics and medication use

Age (years)^a

62 (56–68)

62 (55–68)

Males (%)

74.0

74.8

Caucasian (%)

87.6

87.7

Body mass index (kg/m²)

30.3 ± 5.0

30.2 ± 4.8

Hypertension (%)

87.8

89.4

Dyslipidemia (%)

75.4

74.5

Current or ex-smoker (%)

10.4

12.1

Duration of diabetes (years)

8.7 ± 7.7

84. ± 7.6

Prior myocardial infarction (%)

14.7

14.4

Prior coronary revascularization (%)

21.2

21.4

History of heart failure (%)

14.8

15.1

History of atrial fibrillation (%)

7.2

7.0

History of chronic kidney disease (%)

4.6

5.4

Index ACS event

 STEMI (%)

39.0

38.6

 Non-STEMI (%)

35.4

34.2

 Unstable angina (%)

25.3

26.7

PCI for index ACS (%)

79.2

79.8

Time from index ACS to randomization (days)^a

38 (25–62)

38 (25–63.5)

Medications

 Atorvastatin (%)

51.4

51.2

 Rosuvastatin (%)

48.6

48.8

 High-intensity statin (%)

90.5

89.9

 ACE inhibitor/angiotensin II receptor antagonist (%)

92.0

92.3

 Beta-blockers (%)

90.2

91.0

 Carvedilol, bisoprolol or nebivolol (%)

69.1

67.6

Anti-platelet agents (%)

99.1

98.7

 Dual anti-platelet agents (%)

88.3

87.2

Diuretics (%)

53.5

51.3

Mineralocorticoid receptor antagonists (%)

23.1

21.8

Sacubitril/valsartan

0.3

0.1

Diabetes medications

 Metformin (%)

82.0

83.3

 Insulin (%)

38.5

36.7

 Sulfonlyureas (%)

28.5

30.0

 DPP4 inhibitors (%)

14.8

14.9

 SGLT2 inhibitors (%)

12.3

12.4

 GLP1 receptor agonists (%)

3.7

3.4